跳至主要内容
临床试验/NCT06730516
NCT06730516已完成1 期

Optic Nerve Head Perfusion Following Treatment with Latanoprost 0.005% Versus Brimionidin Tartrate 0.2% in Primary Open Angle Glaucoma: an Optical Coherence Tomography Angiography Study

Zagazig University1 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2024年6月24日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
56
试验地点
1
主要终点
OPTIC NERVE PERFUSION using OCT angiography numerical analysis system presented in %

研究概览

简要总结

This study aimed to evaluate the effects of topical Latanoprost 0.005 % versus Brimionidin tartrate 0.2% on perfusion of optic nerve head This prospective interventional randomized study included 56 naive patients recently diagnosed with bilateral primary open angle glaucoma equally divided into two groups with 28 patients in each group

详细描述

This study aimed to evaluate the effects of topical Latanoprost 0.005 % versus Brimionidin tartrate 0.2% on perfusion of optic nerve head This prospective interventional randomized study included 56 naive patients recently diagnosed with bilateral POAG equally divided into two groups with 28 patients in each group. The whole VD was increased and also increased in all four nasal, temporal, superior, and inferior quadrants around optic disc from the initial vessel density before treatment (p<0.001) in both groups significantly with superior improvement in group (1) compared to group (2) that was statistically significant

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age more than 18 years newly diagnosed naive patients with POAG

排除标准

  • optic nerve lesions other than glaucomatous changes patients with previous glaucoma surgery

研究组 & 干预措施

Latanoprost (Xalatan)

Experimental

Group (1) included 23 patients (46 eyes) treated with Latanoprost 0.005 %

干预措施: Latanoprost (Xalatan) (Drug)

Brimonidine 0.2%

Experimental

24 patients (48 eyes) received treatment with Brimonidin tartrate 0.2% in group (2)

干预措施: Brimonidine 0.2 % (Drug)

结局指标

主要结局

OPTIC NERVE PERFUSION using OCT angiography numerical analysis system presented in %

时间窗: 3 months

perfusion of optic nerve head in patients with primary open angle glaucoma (POAG) using optical coherence tomography angiography (OCTA).

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验